Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis
Clinical trial NCT04617028 · COMPLETED
Trial details
- NCT number
- NCT04617028
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-05
- Primary completion
- 2023-10-18
- Enrollment
- 105
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.